The American Association for Cancer Research Annual Meeting.
Explore this paper's citation graph
Summary
Synta Pharmaceuticals Corp. will present multiple posters at the American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 to be held April 2-6, 2011 in Orlando, FL.
- Type
- article
- Published
- 2013-01-01
- Cited by
- 28
- References
- 0
- OpenAlex
- https://openalex.org/W2801466196
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:42430066
Keywords
Medicine, Internal medicine, Pembrolizumab, Clinical endpoint, Oncology
References
No references recorded for this paper.
Cited by
- Elucidating the regulatory mechanisms of pterygium
- RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors
- Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
- HBV infection increases the risk of pancreatic cancer: a meta-analysis
- Novel therapies, including enzastaurin, in the treatment of ovarian cancer
- Postpartum remodeling, lactation, and breast cancer risk: summary of a National Cancer Institute-sponsored workshop.
- Advances in targeted therapy for melanoma: a focus on MEK inhibition
- Expression of HER2 in Breast Cancer Promotes a Massive Reorganization of Gene Activity and Suggests a Role for Epigenetic Regulation
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- Targeting telomerase in HER2 positive breast cancer: role of cancer stem cells
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Immune checkpoint inhibitors in the treatment of advanced mucosal melanoma.
- Immune control by amino acid catabolism during tumorigenesis and therapy
- A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas
- PAGE-Net: Interpretable and Integrative Deep Learning for Survival Analysis Using HistopathologicalImages and Genomic Data
- Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice
- MIR4435-2HG regulates cancer cell behaviors in oral squamous cell carcinoma cell growth by upregulating TGF-β1
- Colon carcinoma treatment using bispecific anti-GITR/CTLA-4 antibodies: a patent evaluation of WO2018091739
- Desmoplasia and Biophysics in Pancreatic Ductal Adenocarcinoma: Can We Learn From Breast Cancer?
- Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions
Related papers
- Risk of cumulative toxicity after complete melanoma response with pembrolizumab
- Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies
- Out-of-hospital ventricular fibrillation in three adolescents
- Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab
- Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
- Outcomes of patients with non‐melanoma solid tumours receiving self‐funded pembrolizumab at Chris O'Brien Lifehouse
- Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
- Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
- Pembrolizumab Alone or with Chemotherapy for Metastatic Non-Small-Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.